Login to save this article and read it later.
(CercleFinance.com) – bioMérieux declines by more than 2%, penalized by a decline in Berenberg’s recommendation to ‘keep’ to ‘sell’ with a target price of 120 to 110 euros, as the company considers the stock to be the least appreciated in its sector.
The biggest question is what the post-Covid-19 landscape will look like, » warns the broker, who maintains Qiagen as his ‘first choice’ in the European diagnostics sector, and retains its buy recommendations on IP Group and Biocartis.
Copyright (c) 2021 Cercle Finance. The information and analyses published by Cercle Finance are only a decision-making aid for investors. Cercle Finance cannot be held liable directly or indirectly as a result of the use of the information and analyses by the readers. It is recommended to any uninformed person to consult a professional adviser before any investment. This indicative information does not constitute in any way an incitement to sell or a solicitation to buy.